Navigation Links
Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs
Date:11/5/2008

nology" of results demonstrating long-term protection against measles challenge in juvenile and infant nonhuman primates with a Vaxfectin(R)-formulated DNA vaccine.

Conference Call

Vical will conduct a conference call and webcast to discuss the financial results and program updates with invited analysts and institutional investors today, November 5, at noon Eastern Time. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (800) 817-4887, or (913) 312-1277 for international participants, and reference confirmation code 3255394. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (888) 203-1112, or (719) 457-0820 for international participants, and enter replay passcode 3255394. The call also will be available live and archived through the events page at http://www.vical.com. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at info@vical.com.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results
2. Vical to Present at Upcoming Investor Conferences
3. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
4. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
5. Vical to Present at UBS Global Life Sciences Conference
6. Society of Gynecologic Oncologists to Host Cervical Cancer Prevention Forum
7. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
8. Vical to Present at Upcoming Investor Conferences
9. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
10. Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
11. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and PARIS , July ... Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that ... Drug Administration (FDA) rare pediatric disease priority review voucher ... for alirocumab.  The priority review voucher entitles the holder ... for an expedited 6-month review from the filing date ...
(Date:7/30/2014)... FRANCISCO , July 30, 2014 ... Congress evaluated the safety and efficacy of CSL ... rejection following kidney transplants in highly sensitized patients. ... inhibitor of the complement system. The ... in significant increases in the levels of complement ...
(Date:7/30/2014)... 30, 2014 While administrative claims ... services research for a relatively long period of ... regarding the use of these ‘big data’ for ... By combining today’s powerful computer technology with the ... ‘big data’ holds significant promise for identifying optimal ...
(Date:7/30/2014)... July 30, 2014   Wyle has ... Integrated Lifecycle Mission Support Services (FILMSS) contract awarded ... Under the terms of the contract, Wyle will ... Moffett Field, Calif. In particular, Wyle will provide ... development projects on the International Space Station and ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2
... ("Bioponic" or "the Company") (OTC: BPYT) today announced that ... to sales for the month,of January 2007., "We ... primarily,from continued success of our Flight Spray product. We ... an all-natural solution for,baby care marketed under the Gentle ...
... /Xinhua-PRNewswire/ -- China Shenghuo,Pharmaceutical Holdings, Inc. ("China ... in the research, development, manufacture, and,marketing of ... People,s Republic of China ("PRC"), today announced ... products in the United States during the,first ...
... Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned subsidiary of ... received tentative approval from the U.S. Food,and Drug ... and 40 mg (base). Nexium(R) (Esomeprazole) is the,second ... annual market sales of,$5.5 billion (IMS -- MAT: ...
Cached Biology Technology:Bioponic Phytoceuticals Announces Record Sales Increase of 40% for the Month of January 2China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group 2China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group 3Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules 2
(Date:7/30/2014)... Helsinki and the Universitat Autnoma de Barcelona have been ... have taken millions of years to occur. Through small ... teeth, induced in the laboratory, scientists have obtained teeth ... the fossil registry of rodent species which separated from ... the development of their teeth, the team from the ...
(Date:7/30/2014)... to announce its new relationship with the International College ... will partner to publish International Journal of Neuropsychopharmacology ... , Alan Frazer, Editor-in-Chief of IJNP said, ... OUP will further facilitate the goal for the ... journals within neuropsychopharmacology. The conversion of the IJNP ...
(Date:7/30/2014)... has received a pledge of $1 million from the ... Laboratory,s new Neurobehavioral Biometry Center. , The ... enable the Laboratory to develop a greater breadth and ... goal of accelerating the pace of research to improve ... a premier resource for the Laboratory and its external ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2OUP to partner with the International College of Neuropsychopharmacology 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... visual centers of men and women,s brains works is ... access journal Biology of Sex Differences . Men ... stimuli, but women are better at discriminating between colors. ... male sex hormone (androgen) receptors throughout cerebral cortex, especially ...
... for up to twelve weeks could dramatically improve the ... developed the new technology are presenting their work at ... University of Warwick. Researchers at the University of ... urinary bacteria, including most strains of Proteus bacteria ...
... proportion of HIV-infected patients in the U.S. receiving effective ... and HIV-infected patients appeared to be less infectious and ... study led by researchers at the Johns Hopkins Bloomberg ... the NA-ACCORD (North American AIDS Cohort Collaboration on Research ...
Cached Biology News:The eyes have it: Men do see things differently to women 2New long-term antimicrobial catheter developed 2HIV treatment use increases in the US 2
...
... high-throuput screening of a biological systems phenotype, ... changes in the expression levels of the ... studied, classified and compared to each other, ... a glance. Automatized scanning of the hybridized ...
Rabbit polyclonal to Esa1 ( Abpromise for all tested applications)....
RORgamma (S-14)...
Biology Products: